FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Börse Stuttgart 09:12:38 28/05/2024 pm IST | ||
| 2.43 EUR | +5.19% |
|
| Current month | +0.41% | ||
| 1 month | +1.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 2.43 | +5.19% |
| 27/24/27 | 2.31 | -0.43% |
| 24/24/24 | 2.32 | +1.75% |
| 23/24/23 | 2.28 | -1.30% |
| 22/24/22 | 2.31 | +2.67% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 09:12 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SD4ZN2 |
| ISIN | DE000SD4ZN27 |
| Date issued | 26/03/2021 |
| Strike | 7,134 p |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 11.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.86 € |
|---|---|
| Lowest since issue | 2.25 € |
| Spread | 0.03 € |
| Spread % | 1.22% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
170.1
USD
Spread / Average Target
+10.69%
- Stock Market
- Certificates
- Certificat
